INTRODUCTION {#S5}
============

Excessive body weight, the most common pediatric chronic disease ([@R1]), predicts early morbidity and increased mortality ([@R2]). Obesity in youth carries a significant burden of cardiovascular (CV) risk factors ([@R3]), and is associated with premature atherosclerosis ([@R4]). The presence of multiple CV risk factors during childhood is associated with both adult metabolic syndrome ([@R5]) and CV disease events ([@R6]).

Dietary change is the first line therapy to reduce obesity-related CV risk ([@R3]) and lifestyle interventions have been shown to reduce CV risk factors in clinical trials ([@R7]). However, the effects of lifestyle interventions are relatively modest in the research setting, and in clinical practice ([@R8]). The disappointing results of these behaviorally oriented interventions may be related to challenges with adherence -- including adoption and maintenance ([@R9]), or uncertainty about the optimal dietary prescription.

Nutrition prescriptions to reduce CV risk factors have previously focused on reducing dietary fat ([@R10]); however, the results of pediatric low fat (LF) diet studies are disappointing ([@R11]). Some clinicians and investigators have used a low glycemic load (LGL) diet to treat nutrition-related CV risk factors. Glycemic load, a dietary variable that quantifies how a food, meal, or diet affects blood glucose in the postprandial period ([@R12]), has been validated in physiology studies ([@R13]) and may be effective in adults in inducing short-term weight loss ([@R14]), improving CV risk factors ([@R15]), and reducing CV risk ([@R16]) and diabetes ([@R17]). Several pediatric studies suggest a LGL diet may reduce body weight and CV risk factors among adolescents ([@R18], [@R19]); however, these studies have not specifically focused on children with CV risk factors. This study examined the effect of LF and LGL diets during an energy-restricted *Intensive Phase* of food provision to participant homes, followed by an ad libitum *Maintenance Phase*. The aim was to disentangle the effects of dietary composition from variable compliance in the treatment of youth with CV risk factors.

METHODS {#S6}
=======

Study design {#S7}
------------

In this pilot study, children and adolescents with overweight/obesity and additional CV risk factors were randomly assigned to a LF or a LGL diet. Food and nutrition education were delivered directly to the home during an 8-week *Intensive Phase* in a modified feeding protocol, followed by a 4-month *Maintenance Phase* that relied on nutrition education. The primary endpoint of the trial was the difference between the LF and LGL groups in the change from baseline to 8 weeks in insulin sensitivity, represented by the insulin area under the curve (InsAUC) measured during a 2 hour oral glucose tolerance test (OGTT). Additional outcomes included homeostatic model assessment-insulin resistance \[HOMA-IR\] and HgA1c, fasting lipids, blood pressure (BP), and C-reactive protein (CRP). There were 4 study visits: screening, baseline, at the end of the *Intensive Phase* (8 weeks) and at the end of the *Maintenance Phase* (6 months). Study visits and food preparation were conducted at Boston Children's Hospital (BCH) Clinical and Translational Study Unit from May 2007 to March 2012. Written informed consent was obtained from participants or parents. The study was approved by the BCH Institutional Review Board; ([clinicaltrials.gov](http://clinicaltrials.gov) registration NCT01080339).

Participants {#S8}
------------

Participants were recruited from clinical programs treating pediatric obesity and complications, Craigslist, and community practices. Individuals aged 8--21 years were eligible to participate if they had elevated body mass index (BMI) ≥ 85^th^ percentile using CDC reference population, ([@R20]) a fasting insulin ≥ 10 µU/mL, and at least 2 additional CV risk factors. Additional risk factors were defined as 1) fasting triglycerides (TG) \>100 mg/dL, 2) high-density lipoprotein cholesterol (HDL-C) \<50 mg/dL, except for boys ages 15--19 years, in whom the cutpoint was \<45 mg/dL, 3) systolic BP \>90^th^ percentile for gender, age and height ([@R3]), and 4) fasting glucose ≥100 mg/dL or elevated fasting insulin (\>15 µU/mL). Thus all participants had a fasting insulin of at least 10 µU/mL to be considered eligible, and some had an insulin \>15 µU/mL as an additional qualifying factor. Exclusion criteria included weight \>275 lbs. (125 kg) due to concerns about venous access, current or anticipated pregnancy, major medical illness or medications that might significantly affect CV risk factors or weight (e.g. thyroid disorders), alcohol, tobacco, or other drug use, serious food allergy, or abnormalities at screening that indicated a need for pharmacotherapy. For this pilot study, we also excluded participants whom we anticipated would have significant difficulty following the study protocol (e.g. behavioral issues, major food restrictions or aversions) or who lived outside a reasonable driving distance.

Participants were randomized to diet groups using computer-generated assignments prepared by the BCH Clinical Research Center. Randomization was stratified by gender and performed in permutated blocks to support equal distribution between the two study diets over time. Participants were not informed of their group assignment, although some may have guessed based on the food and nutrition information provided. Participants and their families received food, dietary counseling, and parking or public transportation vouchers, iTunes credits and movie vouchers, and a voucher towards physical activity programming at study completion.

Intervention {#S9}
------------

During the *Intensive Phase* all participants received 3 customized meals and 1 snack per day prepared according to their assigned diets (LF or LGL) for 6 out of 7 days per week. On the 7^th^ day participants were instructed to eat along the assigned dietary strategy. Foods and beverages were prepared and portioned in the metabolic kitchen and were delivered as a combination of uncooked staples, and partially and fully prepared meals and snacks delivered in quantities to supply a caloric deficit of \~ 25% to induce modest weight loss over the course of 8 weeks. Energy requirements were calculated based on the Schofield equation for calculating resting energy expenditure ([@R21]); we used an activity factor of 1.2--1.5, adjusted to each participants' reported activity to calculate energy demands. Measures were taken to promote adherence including appropriately portioned planned and "emergency" snacks to prevent eating outside the dietary assignment, the use of a restaurant-style menu developed by a professionally trained chef, provision of lunches suitable for taking to school and family meals twice a week, and the allowance of one "free" day. Dietary change was reinforced by weekly in-person home nutrition counseling and weekly phone calls covering topics consistent with the participant's group assignment using an adapted nutrition curriculum ([@R22]).

During the *Maintenance Phase*, participants were asked to follow their assigned dietary strategy with no provision of food or in-person contact. The study dietitians continued to provide behavioral support by phone at regular intervals (weeks 10, 12, 16, and 20).

### Dietary composition {#S10}

The diets were designed to differ primarily in GL and macronutrient composition (percent fat/carbohydrate/protein; LGL: 40/40/20, LF: 20/60/20). The LGL diet targeted a glycemic index of 50% for each meal, calculated as product of the glycemic index of a food and the amount of carbohydrate in that food using glucose as the reference ([@R23], [@R24]). The LF diet was based on contemporary dietary guidelines (20% total fat of which 7% were saturated fat), ([@R10]) fulfilling recommendations for fiber, fruit and vegetables, limiting total fat, fat type, and cholesterol, and was designed to achieve a GI that reflects prevailing dietary patterns ([@R25]). Aside from differences in GL, total fat and saturated fat content, the study diets were designed to be as similar as possible, providing similar amounts of protein (20%), fiber (\~30 g/day), and dietary cholesterol (≤200 mg/day) ([@R3]), as well as a similar intensity of treatment and palatability of meals. All participants were supplied with Flintstones multivitamins to minimize any potential discrepancies in micronutrients between the diets.

### Physical activity {#S11}

We asked participants to hold physical activity constant as much as possible to avoid confounding of the study outcomes. We assessed activity and inactivity by way of pedometers, which participants were asked to wear for 3 days in the week prior to the baseline, 8-week and 6-month study visits, and by way of self-report using questions from the Youth Risk Behavior Survey ([@R26]).

Measurements {#S12}
------------

### Laboratory testing {#S13}

The primary study outcome was the change from baseline to 8 weeks in insulin sensitivity measured by calculating the area under the curve (AUC) of glucose and insulin from a 2-hour oral glucose tolerance test (OGTT); samples were collected at −20, −10, 0, +10, +20, +30, +60, +90, and +120 minutes after a 75-gram oral dose of Trutol. HOMA-IR was calculated using averaged fasting glucose and insulin values from the −20, −10, and 0 time points. A fasting lipid panel was measured at all study visits according to standard methods. Additional measures included CRP, liver function tests (ALT, AST), and HgA1C.

### Anthropometrics and blood pressure {#S14}

Anthropometrics were measured three times including weight (nearest 0.1 kg), height and waist circumference (nearest 0.1 cm) and the average of each was used in the analysis. Percent body fat was measured in the supine position in the fasting state using bioelectrical impedance (Quantum II, RJL Systems, Inc.). Study nurses measured systolic and diastolic BP by auscultation three times in the right arm in a quiet room after five minutes of rest, according to standard methods ([@R3]), and averaged.

### Process measures {#S15}

Adherence with the dietary assignment was assessed by unannounced dietary recalls interviews conducted by telephone at baseline, 8 weeks and 6 months. Three interviews were done per participant at each time point on two randomly selected weekdays and one weekend day. Dietary intake data were collected using Nutrition Data System for Research (2006--2011, Nutrition Coordinating Center, Minneapolis, MN).

Statistical methods {#S16}
-------------------

Descriptive statistics at baseline by diet group and overall are reported as mean (SD) or frequency (%). Differences between treatment groups on demographic and clinical factors at baseline were assessed using two-sample t-tests for continuous variables and Fisher's exact test for categorical variables. Descriptive statistics for primary and secondary outcome measures at each visit are reported as mean±SE. Variables were assessed for normal distribution, and log-transformed if not normally distributed. Paired t-tests were used to assess pre-post changes from baseline to 8 weeks or 6 months within diet. Differences between diets in pre-post changes from baseline at each visit were assessed using independent t-tests. Selected lipid parameters (where noted in tables) demonstrated skewed distributions and were log transformed for analysis using parametric tests and re-transformed to natural units for reporting. All tests were performed at two-sided alpha-level of 0.05. SAS (version 9.3, Cary, NC) was used for all analyses. Analysis of primary and secondary outcomes was performed with the intention-to-treat principle. The baseline observation was carried forward to impute information for two subjects who missed visits. One subject dropped out prior to the 8 week visit and another dropped out after the 8 week and prior to the 6 month.

The study was designed to recruit 46 patients in order to complete data collection on 40 patients, 20 per group, which would have produced 80% power to detect a difference in mean change of 0.7 multiplied by the coefficient of variation in the primary outcome variables, assuming a pre-post (baseline-8 week) correlation of 0.7 and 5% Type I error rate. The baseline coefficient of variation was 55% for insAUC and 44% for HOMA-IR, making the estimated detectable effects 37% and 30%, respectively.

RESULTS {#S17}
=======

Participants {#S18}
------------

We approached 383 potentially eligible children and adolescents. Of these, 356 were excluded ([Figure 1](#F1){ref-type="fig"}). Common primarily for medications or medical illness (n=104), normalization of CV risk factors at baseline (n=22), and factors that would make it difficult to comply with the requirements of the study (n=56) such as highly restrictive food preferences or major food allergies; some were excluded for multiple reasons. This left 27 participants for randomization. The study was stopped due to slow enrollment. The study reached 59% of target enrollment, and 65% of the number necessary to complete 8 weeks of data collection estimated in the original sample size calculation.

Baseline characteristics {#S19}
------------------------

[Table 1](#T1){ref-type="table"} describes baseline characteristics of all study participants. By design, participants had high rates of CV risk factors, including adiposity (mean BMI 98^th^ percentile and Z score 2.05, percent body fat 35.3%). Many came from families with a history of CV risk factors and events. No differences were detected between the two dietary groups with regard to sociodemographic and anthropometric characteristics, or CV risk factors.

Intensive Phase {#S20}
---------------

Measures of glucose homeostasis -- fasting insulin, insAUC, HOMA-IR, and glycosylated hemoglobin (A1C) -- improved in the study participants overall ([Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). In analyses by group, the LF group showed a greater decrease in fasting glucose (−8.0 ±3.2 mg/dL) than the LGL group (1 ±1.8 mg/dL, p= 0.01 for difference between groups). There were no between-group differences in the change from baseline to 8 weeks in InsAUC, the primary outcome, or in other measures of glucose homeostasis.

Lipid parameters improved over the course of the intervention in the group overall ([Table 2](#T2){ref-type="table"}). The only difference in lipid changes between the two diets was in HDL, which declined/worsened in the LF group by −3.7 ± 1.4 mg/dL, but not in the LGL participants (1.5 ± 1.1 mg/dL; p=0.005 for difference between groups). Improvements in other lipid measures were not statistically significant. CRP declined in the group overall; there was no difference between the LF and LGL groups.

In the group overall (N=27), body weight (−2.7 ± 0.5 kg), BMI (−1.4 ± 0.21 kg/m^2^) and waist circumference (−3.1 ± 0.8 cm) decreased during the 8-week *Intensive Phase* ([Table 3](#T3){ref-type="table"}). There were no significant differences between the LF and LGL groups for mean change in any anthropometric measures. SBP decreased significantly among all participants combined and for the LF group, while DBP decreased significantly in the LGL group. However, between-group comparisons for changes in SBP and DBP were not statistically significant.

Dietary recalls suggested successful implementation of the dietary intervention (see [Supplemental Table](#SD1){ref-type="supplementary-material"}). The LGL diet produced a lower GL than the LF diet, as measured by recall at 8 weeks (47.9 ± 2.4 and 78.1 ±1.4 g/1000 kcal respectively). The LGL group experienced a substantial decline in glycemic load from baseline to 8 weeks of −22.4 ±3.4 g/1000 kcal (p= \<0.001), as expected based on diet design, while there was no change in GL in the LF group (0.84 ±3.6, p=0.82). Added sugars declined in the LGL group (−23.8±4.6, p\<0.0001), but not in the LF group (−8.9±4.2 g/1000 kcal, p=0.06). The difference between diets was significant for both GL and added sugars (p\<0.0001 and p=0.03, respectively). Similarly, percent of total energy intake from saturated fat differed at 8 weeks between the two diets, LGL 10.3 ±0.4% and LF 5.7 ±0.7%. Total fat and saturated fat as a percent of total energy intake declined from baseline to 8 weeks in the LF group (−7.0 ±1.9%, p=0.004 and −3.2 ±0.6%, p=0.010). Percent of total energy intake from protein increased in the LF group (4.0 ±1.5%) and remained stable in the LGL group (p=0.048 for difference). There were significant group differences in change from baseline to 8 week visit between the two diets in reported carbohydrate as a percent of total energy intake (p=0.02), percent total fat (p\<.001), and in mono- (p=0.001), poly- and saturated fat. Physical activity by pedometer and self-report did not change from baseline to 8 weeks in the group overall and there were no between-group differences (data not shown).

Maintenance Phase {#S21}
-----------------

Outcomes tended to return toward baseline during the *Maintenance Phase*, although some benefits persisted. Compared to baseline measures, pooled analysis of all participants showed the group as a whole sustained small benefits in BMI (−0.8 ±0.24, p=0.003), BMI Z-score (−0.13 ±0.03, p\<.001), waist circumference (−2.6 ±0.8 cm, p=0.005), percent body fat (−1.8 ±0.5%, p\<.001), and SBP (−3 ±1.4 mmHg, p=0.04) at the 6 month visit. Improvements in the group overall were also maintained in HDL (2.1 ±0.7 mg/dL, p=0.005), TC/HDL −0.3 ±0.1, p=\<0.001) and TG/HDL (−0.6 ±0.2, p=0.03). Dietary recalls suggested the participants retained improved dietary quality compared to baseline, including lower GL (−6.1±3.1 g/1000 kcal, p=0.06), lower added sugars (−7.52 ±3.8 g/1000 kcal, p=0.06), higher percent calories from protein (2.3 ±1.2, p=0.07); none of these changes reach statistical significance. Energy intake declined in the group overall (−221.6 ±63.4, p=0.002). There were no significant differences between the two diet groups in any of these parameters ([Supplemental Table](#SD1){ref-type="supplementary-material"}).

Discussion {#S22}
==========

Home delivery of a calorie-restricted diet combined with nutrition education over 8 weeks produced important improvements in CV risk factors in high-risk children and adolescents; notably, no consistent differences was demonstrated between the LF and LGL dietary strategy in this pilot study. Improvements in insulin resistance (HOMA-IR), adiposity, lipid measures, and blood pressure from this intensive intervention waned during the maintenance phase when food delivery stopped.

This study was designed to assess difference in insulin sensitivity between the LF and LGL diets. Weight loss studies in adults demonstrate no differential benefit of LF or LGL diets with regard to weight loss in unselected populations ([@R15], [@R27]), although individuals with high insulin secretion may experience more weight loss on LGL diets ([@R28], [@R29]). Some studies in adults suggest differential effects of diet on cardiometabolic risk factors ([@R30]--[@R32]), with LF diets tending to lower TC and LDL ([@R30]) but these improvements may not necessary translate into significant reductions in CV events ([@R33]). Insulin resistance, a key pathophysiologic process in obesity, may be improved by a LGL diet ([@R27], [@R34]--[@R37]), and LGL diets may be associated with fewer CV events, at least in women ([@R16]). Pediatric studies are also mixed, with some reporting benefits of a LGL diet for weight loss and insulin resistance compared to LF dietary advice ([@R22], [@R38]), and other trials showing no benefit ([@R19], [@R39]). None of the previous pediatric studies employed high intensity interventions, and compliance was variable.

This study did not demonstrate superiority of a LF or a LGL diet for CV risk factor reduction, either because of a true lack of differential efficacy, a dominating effect of weight loss on CV risk factors, the short-term nature of the intervention, and/or limited power. When we considered change from baseline in the 25 subjects who completed the study, there was an observed difference of 5% for the primary outcome, resulting in post-hoc power to demonstrate significance for differences of the observed magnitude of only 5--6%. Therefore, a much larger sample would be required for adequate power to test the primary hypothesis. This study faced significant difficulty with recruitment, which not only contributed to low power but also may limit the generalizability of these findings. Interpretation of these results may also be limited by self-reported measures of physical activity and diet, although these measures were complemented by more objective measures (BMI, WC and pedometer data).

Despite limited power to assess differences between diet groups, this intervention produced potentially important improvements in CV risk factors in only 8 weeks, on par with changes produced by pharmacologic therapies ([@R3]), that if sustained, could meaningfully impact the development of cardiometabolic disease among children at risk. We developed this novel intervention strategy as a feasible alternative to a conventionally implemented feeding study design that requires patients to come frequently to a metabolic kitchen, which is logistically challenging for adults and impractical for children. Home food provision was combined with complementary nutrition education to treat children at risk for early atherosclerosis. Implementation of the intervention was successful with very low dropout rates, (n=1 during the *Intensive Phase*), suggesting this model holds promise for future nutrition research. The results of this study are in contrast to nutrition education approaches to reducing CV risk in children and adolescents that have modest and diminishing effects in research studies, and may not produce meaningful change in real-life settings ([@R7], [@R8]).

Novel aspects of our intervention that may have contributed to success included a pragmatic approach to food provision (into the home), allowing for meal choice within the prescribed diets, oversight from a professional chef, and frequent responsive interaction between participants and the research team. As has been seen with most other obesity interventions, benefits to adiposity and other CV risk factors were not sustained and additional support would be required to promote the maintenance of the healthy diet. Home delivery of prepared meals with dietary counseling is not likely to be a feasible intervention for all youth with obesity, but might be useful for high-risk youth who might otherwise be candidates for pharmacologic management or bariatric surgery. Trials of home food delivery in adults show promise ([@R40]). Modifications of this intervention to reduce cost and promote scalability could include delivering staples instead of some of the home meals, the use of the internet or phone to facilitate counseling, and a more skills-based *Maintenance Phase* that includes grocery shopping and cooking demonstrations. Cost effectiveness research is needed to compare such an approach to other available treatments for children with overweight/obesity at risk for CV disease.

In conclusion, this pilot study showed LGL and LF dietary strategies were equally beneficial to children and adolescents in reducing adiposity and other CV risk factors when delivered to the home along with nutrition education. This novel intervention strategy -- utilizing home delivery of meals to supplement conventional nutrition education in a medical or public health setting -- shows early promise but requires additional research.
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###### Baseline participant characteristics

Data are reported for all study participants as n (%), or mean (SD). Family history and sociodemographic characteristics were collected from the parent at the time of the baseline visit.

  Participant Characteristics                                                      (n=27)
  ------------------------------------------------- ------------------------------ ------------
  **Gender**                                        Male                           9 (33%)
  **Age (years)**                                                                  13.2 (2.5)
  **Race/ethnicity**                                White                          13 (48%)
                                                    Black                          5 (19%)
                                                    Other/Multiracial              9 (33%)
                                                    Hispanic                       7 (26%)
  **High risk family history:**                                                    
    **Hypertension**                                                               6 (22%)
    **Lipid disorder**                                                             4 (15%)
    **Heart disease**                                                              13 (48%)
    **Obesity**                                                                    8 (30%)
    **Type 2 Diabetes**                                                            7 (26%)
  **Income**                                        Less than \$40,000             3 (11%)
                                                    \$40,000 -- \$79,999           8 (30%)
                                                    \$80,000 or Above              9 (33%)
                                                    Declined to Answer             7 (26%)
  **Highest Level of Education**                    High School or Below           3 (11%)
                                                    Some College or Trade School   5 (19%)
                                                    College Grad or Above          19 (70%)
                                                                                   
  **Cardiovascular Risk Factors**                                                  
                                                                                   
  **BMI**                                                                          29.8 (3.9)
  **BMI z-score**[\*](#TFN1){ref-type="table-fn"}                                  2.0 (0.3)
  **SBP (mm Hg)**                                                                  105 (7.7)
  **Fasting insulin (µU/mL)**                                                      21 (9.2)
  **Fasting glucose (mg/dL)**                                                      88 (8.3)
  **TG (mg/dL)**                                                                   131 (91.3)
  **HDL (mg/dL)**                                                                  36.6 (5.9)

BMI z score was calculated based CDC growth charts.([@R20])

BMI -- body mass index.

###### Laboratory Parameters

Results are shown at Baseline, 8 week and 6 month study visits shown as mean (SD) and change from baseline to 8 weeks. P-values reflect change from baseline and comparison between the groups.

                                                                    Mean ± SE   Change BL to 8 Weeks                                      
  ----------------------------------------------------------- ----- ----------- ---------------------- ----------- ------------- -------- -------
  **Fasting Insulin (µU/mL)**                                 All   21 ±1.8     14 ±1.6                18 ±2.0     −8 ±1.9       \<.001   
                                                              LGL   24 ±2.8     15 ±2.7                20 ±3.2     −9 ±3.1       0.017    0.582
                                                              LF    18 ±1.5     12 ±1.4                16 ±1.6     −6 ±1.6       0.002    
  **Fasting Glucose (mg/dL)**                                 All   89 ±1.6     86 ±2.1                89 ±1.4     −3 ±1.9       0.163    
                                                              LGL   89 ±2.6     91 ±1.9                91 ±2.0     1 ±1.8        0.468    0.013
                                                              LF    88 ±1.5     80 ±3.4                87 ±1.9     −8 ±3.2       0.030    
  **AUC Insulin (µU/mL \* 120 mins)**                         All   248 ±26.0   185 ±21.3              \-          −59 ±18.2     0.004    
                                                              LGL   279 ±42.2   218 ±34.8              \-          −52 ±26.7     0.072    0.720
                                                              LF    211 ±25.4   145 ±14.5              \-          −66 ±25.3     0.025    
  **AUC Glucose (mg/dL \* 120 mins)**                         All   251 ±8.1    239 ±6.5               \-          −12 ±9.5      0.225    
                                                              LGL   245 ±11.0   242 ±8.7               \-          −3 ±8.4       0.767    0.262
                                                              LF    260 ±11.9   235 ±10.1              \-          −24 ±19.2     0.232    
  **HOMA-IR (mg/dL\*µU/mL)**                                  All   4.7 ±0.4    3.0 ±0.4               4.2 ±0.5    −1.7 ±0.4     \<.001   
                                                              LGL   5.3 ±0.7    3.5 ±0.6               4.6 ±0.8    −1.8 ±0.7     0.023    0.778
                                                              LF    3.9 ±0.3    2.4 ±0.3               3.5 ±0.4    −1.5 ±0.4     0.001    
  **Hemoglobin A1C (%)**                                      All   5.6 ±0.1    5.5 ±0.1               5.7 ±0.1    −0.1 ±0.1     0.032    
                                                              LGL   5.7 ±0.1    5.6 ±0.1               5.8 ±0.1    −0.1 ±0.1     0.104    0.922
                                                              LF    5.5 ±0.1    5.4 ±0.1               5.5 ±0.1    −0.1 ±0.1     0.183    
  **Total Cholesterol (mg/dL)**                               All   158 ±6.9    148 ±7.3               155 ±7.2    −9.9 ±3.6     0.012    
                                                              LGL   160 ±10.1   155 ±10.7              161 ±10.0   −4.5 ±4.8     0.360    0.102
                                                              LF    155 ±9.4    138 ±9.4               148 ±10.5   −16.5 ±5.1    0.008    
  **HDL (mg/dL)**                                             All   36.6 ±1.1   35.8 ±1.2              38.7 ±1.1   −0.8 ±1.0     0.419    
                                                              LGL   36.7 ±1.3   38.2 ±1.3              39.1 ±1.4   1.5 ±1.1      0.168    0.005
                                                              LF    36.6 ±2.0   32.9 ±1.8              38.3 ±2.0   −3.7 ±1.4     0.020    
  **LDL (mg/dL)**[\*](#TFN3){ref-type="table-fn"}             All   92 ±5.2     85 ±5.8                88 ±5.5     −7.5 ±0.3     0.023    
                                                              LGL   94 ±8.0     90 ±9.9                95 ±7.9     −3.4 ±0.2     0.446    0.131
                                                              LF    91 ±6.8     79 ±6.1                80 ±7.4     −12.2 ±0.6    0.013    
  **Triglycerides (mg/dL)**[\*](#TFN3){ref-type="table-fn"}   All   107 ±13.9   93 ±10.2               104 ±11.0   −13.8 ±1.1    0.091    
                                                              LGL   104 ±17.4   89 ±11.7               99 ±14.1    −14.4 ±1.4    0.131    0.880
                                                              LF    112 ±24.8   99 ±19.5               111 ±19.0   −13.1 ±2.0    0.389    
  **VLDL (mg/dL)**[\*](#TFN3){ref-type="table-fn"}            All   20 ±2.4     19 ±2.1                21 ±2.2     −2.5 ±0.2     0.124    
                                                              LGL   21 ±3.6     18 ±2.4                20 ±2.8     −2.8 ±0.3     0.151    0.817
                                                              LF    20 ±3.6     20 ±3.9                22 ±3.8     −2.0 ±0.3     0.481    
  **Non-HDL Cholesterol (mg/dL)**                             All   121 ±6.9    112 ±7.3               116 ±7.1    −9.1 ±3.2     0.010    
                                                              LGL   123 ±10.2   117 ±10.8              122 ±9.9    −6.1 ±4.5     0.200    0.312
                                                              LF    118 ±9.2    105 ±9.6               109 ±10.1   −12.8 ±4.6    0.018    
  **Total Cholesterol/HDL Ratio**                             All   4.4 ±0.2    4.2 ±0.2               4.1 ±0.2    −0.2 ±0.1     0.171    
                                                              LGL   4.4 ±0.3    4.1 ±0.3               4.2 ±0.3    −0.3 ±0.2     0.076    0.214
                                                              LF    4.3 ±0.3    4.3 ±0.4               3.9 ±0.3    0.0 ±0.2      1.000    
  **Triglyceride/HDL Ratio**                                  All   3.8 ±0.6    3.2 ±0.4               3.2 ±0.4    −0.6 ±0.3     0.116    
                                                              LGL   3.5 ±0.6    2.7 ±0.4               3.0 ±0.5    −0.8 ±0.4     0.058    0.374
                                                              LF    4.1 ±1.0    3.9 ±0.9               3.5 ±0.7    −0.2 ±0.6     0.728    
  **ALT (U/L)**                                               All   27 ±5.5     23 ±3.8                23 ±4.4     −3.7 ±2.3     0.116    
                                                              LGL   34 ±9.6     27 ±6.6                28 ±7.7     −6.1 ±3.9     0.146    0.267
                                                              LF    18 ±1.6     17 ±2.1                17 ±1.9     −0.8 ±1.4     0.576    
  **Fibrinogen (mg/dL)**                                      All   327 ±12.5   321 ±12.8              316 ±12.8   −12.6 ±9.1    0.178    
                                                              LGL   328 ±20.2   332 ±16.3              332 ±19.1   −6.3 ±9.8     0.533    0.483
                                                              LF    326 ±14.3   308 ±20.3              293 ±12.1   −19.5 ±15.9   0.249    
  **CRP (mg/dL)**                                             All   0.3 ±0.1    0.2 ±0.1               0.2 ±0.1    −0.1 ±0.1     0.040    
                                                              LGL   0.4 ±0.2    0.2 ±0.1               0.2 ±0.1    −0.2 ±0.1     0.079    0.271
                                                              LF    0.2 ±0.1    0.1 ±0.0               0.1 ±0.1    −0.1 ±0.0     0.280    

Log-transformed for analysis, re-transformed to standard units.

Testing for zero mean change within diet group.

Testing for equal mean change between diets.

ALT -- alanine aminotransferase, AUC -- area under the curve, CRP -- C-reactive protein, HDL -- high-density lipoprotein, HOMA-IR -- homeostatic model assessment-insulin resistance, LDL -- low-density lipoprotein.

###### Anthropometrics and Blood Pressure

Data are presented as mean ± standard error (SE). Baseline, 8 week and 6 month study visits shown as mean (SD) and change from baseline to 8 weeks. P-values reflect change from baseline and comparison between the groups.

                                                         Mean ± SE    Change BL to 8 Weeks                                       
  ------------------------------------------------ ----- ------------ ---------------------- ------------ ------------- -------- -------
  **BMI**[c](#TFN9){ref-type="table-fn"}           All   29.8 ±0.74   28.4 ±0.79             29.0 ±0.77   −1.4 ±0.21    \<.001   
                                                   LGL   30.7 ±1.22   29.3 ±1.30             30.0 ±1.27   −1.4 ±0.32    \<.001   0.972
                                                   LF    28.7 ±0.61   27.4 ±0.65             27.8 ±0.59   −1.4 ±0.29    \<.001   
  **BMI z-score**[c](#TFN9){ref-type="table-fn"}   All   2.05 ±0.05   1.89 ±0.06             1.92 ±0.05   −0.16 ±0.03   \<.001   
                                                   LGL   2.09 ±0.06   1.93 ±0.09             1.98 ±0.08   −0.16 ±0.04   0.003    0.976
                                                   LF    1.99 ±0.09   1.83 ±0.08             1.84 ±0.06   −0.16 ±0.03   \<.001   
  **Weight (kg)**                                  All   79.3 ±3.5    76.6 ±3.6              79.0 ±3.5    −2.7 ±0.5     \<.001   
                                                   LGL   82.0 ±4.9    79.2 ±5.1              81.7 ±5.1    −2.8 ±0.7     0.002    0.873
                                                   LF    76.0 ±5.0    73.3 ±5.1              75.5 ±4.8    −2.6 ±0.7     0.002    
  **Waist Circumference (cm)**                     All   99.8 ±1.8    96.7 ±1.9              97.2 ±1.8    −3.1 ±0.8     \<.001   
                                                   LGL   100.6 ±2.7   97.3 ±2.9              98.1 ±2.9    −3.4 ±0.9     0.002    0.721
                                                   LF    98.7 ±2.3    96.0 ±2.3              96.1 ±2.1    −2.8 ±1.5     0.084    
  **Percent Body Fat**                             All   35.3 ±0.6    34.2 ±0.6              33.5 ±0.7    −1.1 ±0.4     0.004    
                                                   LGL   36.3 ±0.9    35.5 ±0.9              34.7 ±1.0    −0.9 ±0.5     0.071    0.461
                                                   LF    34.2 ±0.8    32.7 ±0.7              32.2 ±0.8    −1.4 ±0.6     0.030    
  **Systolic BP (mm Hg)**                          All   105 ±1.5     101 ±1.4               102 ±1.3     −5 ±1.4       0.002    
                                                   LGL   106 ±2.0     102 ±1.6               102 ±1.5     −4 ±1.8       0.052    0.443
                                                   LF    105 ±2.3     99 ±2.3                103 ±2.4     −6 ±2.1       0.017    
  **Diastolic BP (mm Hg)**                         All   69 ±1.4      67 ±1.1                67 ±1.2      −2 ±1.3       0.147    
                                                   LGL   70 ±2.2      66 ±1.7                67 ±1.2      −4 ±1.6       0.028    0.078
                                                   LF    67 ±1.3      68 ±1.3                67 ±2.3      1 ±1.9        0.756    

Testing for zero mean change within diet group.

Testing for equal mean change between diets.

BMI and z scores were calculated based on CDC growth charts.([@R20])

BMI -- body mass index, BP -- blood pressure

What is Known on This Subject {#S24}
=============================

-   Dietary improvement is recommended to treat cardiovascular (CV) risk factors during childhood.

-   Low saturated fats were primarily recommended in the past; more recently a low glycemic load approach has been advised.

-   The optimal dietary strategy for improving CV risk factors in youth is not known.

What This Study Adds {#S25}
====================

-   Neither dietary strategy was superior; both produced significant weight loss and improvement in CV risk factors.

-   Home delivery of food and nutrition education holds promise as an alternative to conventional approaches to nutrition research and for the treatment of high-risk youth.
